Antengene ATG-022 CLDN18.2 ADC Gets China Nod for Keytruda Combo in Gastric Cancer
Antengene Corporation Limited (HKG: 6996) announced that China’s National Medical Products Administration (NMPA) has approved...
Combination therapy
Imugene and JW Therapeutics Partner to Evaluate onCARlytics CAR‑T Combination for Advanced Solid Tumors
Imugene Ltd (ASX: IMU) and JW Therapeutics (Shanghai) Co., LTD (HKG: 2126) announced a co‑development...
Pfizer-Astellas’ PADCEV Wins FDA Approval for Perioperative Bladder Cancer
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced that the U.S. Food...
Hengrui’s HRS-6209 CDK4 Inhibitor Wins NMPA Nod for Breast Cancer Combo Trial
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS‑6209 capsules, a novel...
BeOne’s Zanidatamab Achieves PFS & OS Wins in HERIZON-GEA-01 Phase 3 HER2-Positive Cancer Trial
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced its HER2‑targeted bispecific antibody zanidatamab (Ziihera)...
Hengrui Gets NMPA Green Light for Rezvilutamide‑HS‑20093 Combination Trial in Prostate Cancer
China‑based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced today that the China...
Eisai and Merck Present 5‑Year Survival Data for Lenvatinib‑Pembrolizumab in Advanced Endometrial Carcinoma at ESMO 2025
At the European Society for Medical Oncology (ESMO) 2025 Congress, Eisai (TYO: 4523) and Merck,...
Roche Secures FDA Approval for Tecentriq‑Lurbinectedin Combo in ES‑SCLC
Roche (SWX: ROG, OTCMKTS: RHHBY) announced today that the U.S. Food and Drug Administration (FDA)...
HanX Biopharmaceuticals Secures NMPA Approval for HX044‑HX008 PD‑1 Therapy Combination in Advanced Solid Tumors
HanX Biopharmaceuticals (Wuhan) Co., Ltd., a fast‑growing Chinese biotech, announced that the National Medical Products...
Betta Pharmaceuticals Secures NMPA Approval for MCLA‑129/Ensartinib Combination in Advanced Solid Tumors
China-based Betta Pharmaceuticals (SHE: 300558) announced that China’s National Medical Products Administration (NMPA) has approved...
Suzhou Zelgen’s ZG005 and Gecacitinib Win NMPA Approval for Advanced Solid Tumors
On August 21, 2025, Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266), a China-based company, announced...
HutchMed Completes Patient Enrollment for Orpathys and Tagrisso Combination Study
Chinese pharmaceutical company HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced the completion of patient...
Hengrui’s Trastuzumab Rezetecan and Adebrelimab Granted Breakthrough Therapy Designation by China’s NMPA
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced on August 11, 2025,...
Johnson & Johnson’s Rybrevant Approved by China’s NMPA for EGFR-Mutant NSCLC Treatment
US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that China’s National Medical Products Administration...
Hengrui Pharmaceuticals Gains NMPA Approval for Phase Ib/II Study of SHR-A1811, Adebrelimab and Famitinib in Solid Tumors
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from...
Antengene and MSD Collaborate on ATG-022 for Advanced Solid Tumors
China-based Antengene Corporation Limited (HKG: 6996) has entered into a collaboration with US major Merck,...
Minghui Pharmaceutical Launches Phase II Study of Combination Therapy for Advanced NSCLC
China-based Minghui Pharmaceutical Inc. announced the initiation of a Phase II clinical study to evaluate...
RemeGen’s Disitamab Vedotin Phase III Study Meets PFS and OS Endpoints
China-based RemeGen Ltd (HKG: 9995) announced that its Phase III clinical study for the antibody...
NMPA Grants Hengrui Pharmaceuticals Approval for Adebrelimab Combination Trials
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from...
Shouyao Holdings Gets Ethics Approval for SY-5933 Phase Ib/II Study in KRAS G12C Mutated Tumors
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) announced that it has received ethical approval...